> Details

Dhingra, Nitish [Author]; Verma, Subodh [Author]; Butler, Javed [Author]; Anker, Stefan D. [Author]; Ferreira, Joao Pedro [Author]; Filippatos, Gerasimos [Author]; Januzzi, James L. [Author]; Lam, Carolyn S. P. [Author]; Sattar, Naveed [Author]; Zaremba-Pechmann, Liliana [Author]; Böhm, Michael [Author]; Nordaby, Matias [Author]; Brückmann, Martina [Author]; Pocock, Stuart J. [Author]; Zannad, Faiez [Author]; Packer, Milton [Author]

Efficacy and safety of empagliflozin according to background diuretic use in HFrEF

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Efficacy and safety of empagliflozin according to background diuretic use in HFrEF : post-hoc analysis of EMPEROR-reduced
  • Contributor: Dhingra, Nitish [Author]; Verma, Subodh [Author]; Butler, Javed [Author]; Anker, Stefan D. [Author]; Ferreira, Joao Pedro [Author]; Filippatos, Gerasimos [Author]; Januzzi, James L. [Author]; Lam, Carolyn S. P. [Author]; Sattar, Naveed [Author]; Zaremba-Pechmann, Liliana [Author]; Böhm, Michael [Author]; Nordaby, Matias [Author]; Brückmann, Martina [Author]; Pocock, Stuart J. [Author]; Zannad, Faiez [Author]; Packer, Milton [Author]
  • Published: January 2024
  • Published in: American College of Cardiology: JACC Heart failure ; 12(2024), 1 vom: Jan., Seite 35-46
  • Language: English
  • DOI: 10.1016/j.jchf.2023.06.036
  • Identifier:
  • Keywords: diuretic agents ; empagliflozin ; heart failure with reduced ejection fraction
  • Origination:
  • Footnote: Online verfügbar: 13. September 2023, Artikelversion: 2. Januar 2024
  • Description: Background - The EMPEROR-Reduced (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction) trial established the efficacy of empagliflozin in reducing heart failure (HF) outcomes among patients with heart failure with reduced ejection fraction (HFrEF). - Objectives - The authors examined the outcomes of EMPEROR-Reduced as a function of background diuretic therapy. - Methods - The EMPEROR-Reduced trial was a double-blind, randomized controlled trial of placebo vs empagliflozin 10 mg among 3,730 HFrEF patients. Herein, the population was stratified into 4 groups: no diuretic and diuretic dose equivalent to furosemide <40, 40, and >40 mg daily at baseline. - Results - A total of 3,656 patients from the EMPEROR-Reduced trial were available for analysis. Of those patients, 482 (13.2%) were receiving no diuretic therapy, and 731 (20.0%), 1,411 (38.6%), and 1,032 (28.2%) were receiving <40 mg, 40 mg, and >40 mg, respectively. The efficacy of empagliflozin on the primary outcome (time to first event of hospitalization for HF or cardiovascular [CV] death) was consistent regardless of background diuretic therapy (>40 mg: HR: 0.88 [95% CI: 0.71-1.10]; 40 mg: HR: 0.65 [95% CI: 0.51-0.82]; <40 mg: HR: 0.65 [95% CI: 0.46-0.92]); no diuretic agents: HR: 0.78 [95% CI: 0.47-1.29]; Ptrend test = 0.192). Baseline diuretic doses did not influence the effect of empagliflozin on body weight, systolic blood pressure, NT-proBNP, or hematocrit at 52 weeks. The safety profile of empagliflozin vs placebo was unaffected by baseline diuretic dose; however, independently of treatment allocation, total rates of adverse events were higher among patients with higher baseline doses of diuretic agents. - Conclusions - Empagliflozin exhibits a consistent effect on time to CV death or HF hospitalization and an unaltered safety profile regardless of baseline diuretic therapy.
  • Access State: Open Access